All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 2022 ASCO Annual Meeting, the Lymphoma Hub spoke with Alison Moskowitz, Feinstein Institutes for Medical Research, New York, US. We asked, What are the latest treatment advances for Hodgkin lymphoma?
What are the latest treatment advances for Hodgkin lymphoma?
Moskowitz begins by discussing the evolution of treatment for Hodgkin lymphoma and the impact positron emission tomography (PET)-adapted therapy has had in the field. Moskowitz outlines recent studies and new therapies that are significantly changing the treatment landscape.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Treating classical Hodgkin lymphoma that is refractory to salvage chemotherapy
As part of our biannual steering committee meeting, Astrid Pavlovsky, Fundaleu, Beunos Aires, AR, chaired a case study discussion session on treating a patient with...
Non-myeloablative haploidentical or unrelated cord blood hematopoietic transplant for Hodgkin and non-Hodgkin lymphoma
A retrospective analysis comparing the outcomes of patients with HL or NHL who underwent non-myeloablative haplo or UCB allo-HSCT.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox